|
|
Phibro Animal Health Corporation (NASDAQ: PAHC) |
|
Price: $38.5800
$-1.34 
-3.357%
|
| Day's High:
| $40.5
| Week Perf:
| 2.42 %
|
| Day's Low: |
$ 38.20 |
30 Day Perf: |
7.14 % |
| Volume (M): |
174,639 |
52 Wk High: |
$ 60.08 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$41.59 |
| Open: |
$40.24 |
52 Wk Low: |
$28.25 |
|
|
| Market Capitalization (Millions $) |
1,580 |
| Shares
Outstanding (Millions) |
41 |
| Employees |
2,605 |
| Revenues (TTM) (Millions $) |
1,517 |
| Net Income (TTM) (Millions $) |
100 |
| Cash Flow (TTM) (Millions $) |
-13 |
| Capital Exp. (TTM) (Millions $) |
59 |
Business Description
Phibro Animal Health Corporation is a world renowned animal health and nutrition company that focuses on the development, manufacturing and marketing of a wide range of innovative animal health products for livestock, poultry, aquaculture and pet industries worldwide.
The company was founded in 1946 and has been steadily expanding its operations to reach a global network of customers and partners through its subsidiaries in the Americas, Europe, the Middle East, and Asia.
Phibro Animal Health is organized into three main business segments: Animal Health, Nutrition, and Performance Products. Under the Animal Health segment, the company provides veterinary products and solutions such as antibiotics, vaccines, and parasiticides that help improve animal health and productivity.
The company's Nutrition segment offers various premixes, concentrates, and feed additives designed to enhance the nutritional value of animal feed and improve the performance of livestock and aquaculture.
Under the Performance Products segment, Phibro Animal Health provides non-antibiotic growth promoters, mold inhibitors, and other additives that help enhance animal health and growth without contributing to antibiotic resistance.
Phibro Animal Health boasts a vast portfolio of more than 2,500 products that cater to a vast array of animal species, including cattle, swine, poultry, fish, pets, among others. The company's focus on research and development has resulted in many groundbreaking products that have revolutionized the animal health and nutrition industry.
Phibro Animal Health Corporation operates under a core set of values that prioritize animal health, customer satisfaction, and employee well-being. The company is committed to sustainability and ethical business practices that ensure the long-term well-being of the environment and communities where it operates.
Overall, Phibro Animal Health Corporation is a reliable and innovative company that provides top-quality animal health and nutrition products and solutions that help farmers, ranchers, and businesses maximize animal health and productivity while optimizing profitability.
Company Address: Glenpointe Centre East, 3rd Floor Teaneck 7666 NJ
Company Phone Number: 329-7300 Stock Exchange / Ticker: NASDAQ PAHC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dividend
Published Wed, Jul 31 2024 5:06 AM UTC
TEANECK, N.J. In a recent announcement that resonates positively with investors, the Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. This decision, effective September 25, 2024, for shareholders on record as of the close of business on Se...
|
| Business Update
Published Thu, Jun 6 2024 12:38 AM UTC
In a recent press release, Phibro Animal Health Corporation proudly announced the release of its third annual Environmental, Social, and Governance (ESG) Report, showcasing the company s accomplishments in 2023. Recognizing the interconnectedness between people, animals, and the planet, Phibro strives to optimize animal health and nutrition for a better future and a sustaina...
|
| Business Update
Published Wed, Jun 5 2024 8:38 PM UTC
Phibro Animal Health Corporation s Third Annual ESG Report Highlights Commitment to Animal Health, Nutrition, and SustainabilityPhibro Animal Health Corporation, a leading provider of animal health and nutrition solutions, is proud to release its third annual Environmental, Social, and Governance (ESG) Report, showcasing their accomplishments in 2023. The report demonstrate...
|
| Business Update
Published Mon, Apr 29 2024 4:08 AM UTC
Zoetis, a leading animal health company, recently announced its decision to sell its medicated feed additive (MFA) product portfolio to Phibro Animal Health Corporation in a definitive agreement worth $350 million. The acquisition includes certain water-soluble products and related assets and is expected to be completed in the second half of the calendar year 2024. This stra...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
2.44 $ |
| Revenues (TTM) |
37.03 $
|
| Cash Flow (TTM) |
- |
| Cash |
2 $
|
| Book Value |
9.41 $
|
| Dividend (TTM) |
0.48 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
582,288 |
| Net
Income per Employee (TTM) |
38,280 |
| Receivable Turnover Ratio (TTM) |
6.7 |
| Inventory Turnover Ratio (TTM) |
2.02 |
| Asset Turnover Ratio (TTM) |
1.02 |
|
|
| Per Share |
|
| Earnings (TTM) |
2.44 $
|
| Revenues (TTM) |
37.03 $ |
| Cash Flow (TTM) |
- |
| Cash |
2 $
|
| Book Value |
9.41 $ |
| Dividend (TTM) |
0.48 $ |
|
|
| |
| Medicated Feed Additives and Others |
|
 204.34 % |
of total Revenue |
| Nutritional Specialties |
|
49.17 % |
of total Revenue |
| Vaccines |
|
39.43 % |
of total Revenue |
| Animal Health |
|
292.94 % |
of total Revenue |
| Mineral Nutrition |
|
71.16 % |
of total Revenue |
| Performance Products |
|
18.53 % |
of total Revenue |
| US |
|
221.08 % |
of total Revenue |
| Latin America and Canada |
|
85.87 % |
of total Revenue |
| EMEA |
|
47.37 % |
of total Revenue |
| Asia Pacific |
|
28.32 % |
of total Revenue |
| |
On February 6 2025 the Phibro Animal Health provided following guidance
nnPhibro Animal Health Corporation Reports Second Quarter Results and Offers Revised Financial Outlooknn
TEANECK, N.J. – On February 6, 2025, Phibro Animal Health Corporation (Nasdaq: PAHC) revealed its financial performance for the second quarter concluded on December 31, 2024, along with a revised financial outlook for the fiscal year ending June 30, 2025. The company reported a robust increase in net sales and net income for the quarter when compared to the same period last year.
nnFinancial Highlights for the Quarter Ended December 31, 2024:nn
- nnNet Sales:nn Phibro achieved net sales of $309.3 million, which reflects a significant rise of $59.3 million or 24% compared to th...
|
|
|
1.87%